Find a Doctor:   

      Search
Home | Doctors | Dr Srividya N


About Doctor:

Dr Srividya N is a Medical Oncologist at MCI Nellore. She has been contributing to the field of Medical Oncology for over 9 years. Her field of expertise includes breast oncology, and gynecological oncology while focusing on preventive oncology and Specialized in chemotherapy, targeted therapy, immunotherapy in the management of breast, lung, gastrointestinal, genitourinary, bone cancers.

Languages:

English, Telugu, Hindi

Specialized Area:

  • Chemotherapy
  • Targeted therapy Immunotherapy
  • Colon & GI Cancer
  • Kidney & GU Cancer
  • Breast Cancer Treatment
  • Lung cancer
  • Leukemia
  • Lymphoma
  • Myeloma
  • Pediatric oncology
  • Cancer Screening
  • Ovary Cancer
  • Bone Cancer
  • Thyroid Cancer Palliative treatment Transplant

Past Experience:

  • Worked as Consultant Medical Oncologist at HCG Curie City Cancer Center, Vijayawada.(2015-2021)
  • Working as Consultant Medical Oncologist at Medicover Cancer Institute, Nellore(2021- to present)

Publications:

  • Response to Imatinib Mesylate in Childhood Chronic Myeloid Leukemia in Chronic Phase”, South Asian J Cancer 2014 Oct;3(4):203-5.
  • Impact of Imatinib compliance on the cytogenetic response at six months in pediatric CML CP. Indian Journal of Pediatrics 2016 Feb 3. DOI 10.1007/s12098-015-2007-9.
  • Impact of treatment protocol on outcome of localized Ewing’s sarcoma. South Asian J Cancer 2016;5:194-5
  • Trends in management of acute lymphoblastic leukemia: Influence of Insurance based healthcare and treatment compliance on the outcome of adolescents and aduls with acute lymphoblastic leukemia. Indian J Med Paediatr Oncol 2016 Jan-Mar; 37 (1):32-7
  • Cytogenetic and Molecular response among EUTOS risk groups in children with CML CP on Imatinib treatment. Egypt J Haematol 2017;42:74-7.
  • Effectiveness of three prognostic scoring systems in predicting the response and outcome in pediatric CML CP on frontline Imatinib. Indian J Med Paediatr Oncol 2017;38:282-6.Imatinib dose hike in suboptimal response and failure in CML CP: Results from a developing nation. journal of Clinical oncology 31,2013_suppl e18003
  • Cytogenetic and molecular response rates in AYA CML CP patients on imatinib based on the baseline BMI”, Annals of Oncology, Volume 27, Issue suppl_9, December 2016, mdw586.009,
  • Safety and efficacy of Carboplatin, Capecitabine plus Cetuximab biweekly regimen in the first-line treatment of patients with recurrent/metastatic head and neck cancer (R/MSCCHN): Single center, retrospective study. Annals of Oncology, Volume 29, Issue suppl_9, November 2018, mdy438.029.
  • Prognostic significance of NLR kinetics in operable triple negative breast cancer. e14201 journal of Clinical oncology 37,2019, no.15_suppl.
Second Opinion
WhatsApp
Book Now